McKesson Corporation (MCK)
NYSE:MCK
Want to see MCK full AI Analyst Report?
Earnings Data
Report Date
Aug 05, 2026Before Open (Confirmed)
Period Ending
2027 (Q1)Consensus EPS Forecast
9.6Last Year’s EPS
8.26Same Quarter Last Year
Strong Buy
Based on 12 Analysts Ratings
Earnings Call Summary
Earnings Call Sentiment|Positive
McKesson reported a strong fiscal 2026 with double-digit revenue, operating profit and EPS growth, robust cash generation and material progress on strategic initiatives (oncology expansion, biopharma scale, supply chain modernization, and Medical‑Surgical separation). The company is returning significant capital to shareholders and reaffirmed long‑term targets. Offsetting risks include branded pricing pressure (IRA effects), sequential GLP‑1 volatility, ongoing integration and corporate expense investments, and near‑term cash flow/interest impacts related to separation financing. On balance the positives (broad-based growth, margin expansion, cash returns, strategic progress) outweigh the negatives, though the business faces near-term variability and execution/approval risks tied to the Medical‑Surgical separation.Company Guidance
Strong Full-Year Financial Performance
Consolidated fiscal 2026 revenues of $403.0 billion, up 12% year-over-year; adjusted operating profit grew 15% to $6.5 billion; adjusted earnings per diluted share increased 18% to $39.11 (20% ex-McKesson Ventures fiscal 2025 gains).
Robust Quarterly Results
Fourth quarter revenues were $96.3 billion, up 6% year-over-year; Q4 adjusted earnings per diluted share were $11.69, up 16% year-over-year; gross profit grew 14% to $3.9 billion and operating profit increased 13% to $1.8 billion.
Cash Generation and Capital Returns
Operating cash flow of $6.2 billion (management commentary) and fiscal 2026 free cash flow of $5.4 billion; returned $5.1 billion to shareholders in fiscal 2026 (share repurchases and dividends), executed $2.25 billion accelerated share repurchase in Q4 and received Board approval for an additional $5.0 billion repurchase authorization (total authorization ~ $7.7 billion).
Oncology & Multispecialty Momentum
Oncology and multispecialty segment revenue increased 35% in Q4 to $12.7 billion and operating profit rose 53% to $385 million; added more than 570 providers in fiscal 2026 (largest net increase since 2010); acquisitions (PRISM and Core Ventures) materially contributed (~13% of Q4 growth and ~34% of segment operating profit growth for FY).
Biopharma Services Scale and Productivity Gains
Delivered record annual verifications supporting a record 3.4 million patients; helped patients save ~ $10 billion on brand and specialty medicines (majority non-GLP-1), prevented ~12 million prescription abandonments and enabled access ~135 million times; each FTE supported ~120 more patients this season vs prior year.
GLP-1 and Specialty Growth
GLP-1 distribution revenues were $14 billion in Q4 (+22% YoY) and fiscal 2026 GLP-1 revenues were $53 billion (+27% YoY); North American Pharmaceutical segment operating profit increased 11% to $980 million with modest margin expansion (+9 bps).
Operational Modernization and Supply Chain Resiliency
Launched new Montreal distribution center with advanced automation and AI-driven storage/retrieval; implemented AI-driven integrated planning system contributing to working capital savings and improved resiliency; successfully managed major winter weather event with limited customer disruption.
Progress on Medical-Surgical Separation and Strategic Partnerships
Completed financing steps toward separation ($1.0B Term Loan A and $1.0B revolving facility) and announced a $1.25B Apollo minority investment (~13% stake) valuing NewCo at ~$13B, positioning the business for an eventual IPO and enabling capital deployment (proceeds expected to support share repurchases).
MCK Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
MCK Earnings-Related Price Changes
Report Date | Price 1 Day Before | Price 1 Day After | Percentage Change |
|---|---|---|---|
May 07, 2026 | $754.76 | $736.09 | -2.47% |
Feb 04, 2026 | $821.32 | $957.00 | +16.52% |
Nov 05, 2025 | $842.77 | $857.10 | +1.70% |
Aug 06, 2025 | $701.68 | $661.29 | -5.76% |
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
FAQ
When does McKesson Corporation (MCK) report earnings?
McKesson Corporation (MCK) is schdueled to report earning on Aug 05, 2026, Before Open (Confirmed).
What is McKesson Corporation (MCK) earnings time?
McKesson Corporation (MCK) earnings time is at Aug 05, 2026, Before Open (Confirmed).
Where can I see when companies are reporting earnings?
You can see which companies are reporting today on our designated earnings calendar.
What companies are reporting earnings today?
You can see a list of the companies which are reporting today on TipRanks earnings calendar.
What is MCK EPS forecast?
MCK EPS forecast for the fiscal quarter 2027 (Q1) is 9.6.